Related Experiment Videos
Hyperbaric oxygen in chronic progressive multiple sclerosis: visual evoked potentials and clinical effects.
Journal of Neurology, Neurosurgery, and Psychiatry
|June 1, 1985
Summary
Hyperbaric oxygen therapy did not significantly improve visual evoked potentials in patients with multiple sclerosis. The treatment also did not halt disease progression and showed more deterioration in the treatment group.
Area of Science:
- Neurology
- Oxygen therapy
Background:
- Multiple sclerosis (MS) is a chronic, progressive neurological disease.
- Current treatments for MS aim to manage symptoms and slow disease progression.
Purpose of the Study:
- To investigate the efficacy of hyperbaric oxygen therapy (HBOT) in patients with chronic progressive multiple sclerosis.
- To assess the impact of HBOT on visual evoked potential (VEP) latencies and disease progression.
Main Methods:
- A randomized controlled trial was conducted involving patients with chronic progressive multiple sclerosis.
- Patients received hyperbaric oxygen at two atmospheres absolute or a placebo treatment.
- Visual evoked potentials were measured to assess neurological function.
Main Results:
- A slight, statistically insignificant reduction in VEP latencies was observed after HBOT compared to placebo.
- HBOT did not demonstrably halt the progression of multiple sclerosis.
- A higher incidence of disease deterioration was noted in the HBOT group versus the control group.
Conclusions:
- Hyperbaric oxygen therapy at two atmospheres absolute is not effective for treating chronic progressive multiple sclerosis.
- HBOT did not show benefits in improving VEP latencies or preventing disease progression.
- Further research may be needed to explore other therapeutic approaches for MS.